Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has made a 26.02% comeback from a 12-month low price of $1.96. It was seen 3.35% higher, changing the price to $2.47, when the closing bell rang on 4/12/2019. At a recent session, the prices were hovering between $2.38 and $2.5. This company shares are 237.25% off its target price of $8.33 and the current market capitalization stands at $399.89M. The recent change has given its price a 5.01% lead over SMA 50 and -47.22% deficit over its 52-week high. The stock witnessed 7.39% gains, 12.27% gains and -19.02% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found RIGL’s volatility during a week at 4.67% and during a month it has been found around 5.22%.

Rigel Pharmaceuticals, Inc. (RIGL) Top Holders

Institutional investors currently hold around $392 million or 97.8% in RIGL stock. Look at its top three institutional owners: Fmr Llc owns $61.74 million in Rigel Pharmaceuticals, Inc., which represents roughly 15.44% of the company’s market cap and approximately 15.75% of the institutional ownership. Similar statistics are true for the second largest owner, Wellington Management Group Llp, which owns 23,328,436 shares of the stock are valued at $57.62 million. The third largest holder is Blackrock Inc., which currently holds $33.9 million worth of this stock and that ownership represents nearly 8.48% of its market capitalization.

Rigel Pharmaceuticals, Inc. 13F Filings

At the end of December reporting period, 67 institutional holders increased their position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) by some 11,090,271 shares, 49 decreased positions by 8,917,594 and 33 held positions by 138,684,627. That puts total institutional holdings at 158,692,492 shares, according to SEC filings. The stock grabbed 16 new institutional investments totaling 1,112,271 shares while 16 institutional investors sold out their entire positions totaling 4,180,591 shares.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Insider Trades

Multiple company employees have indulged in significant insider trading. Rigel Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Principal Accounting Officer Cabatuan Nelson has sold 10,000 shares of Rigel Pharmaceuticals, Inc. (RIGL) in the trading session dated Oct. 12, 2018. These shares are worth $31,200 and were traded at $3.12 each. The SEC filing shows that Duliege Anne-Marie performed a sale of 153,000 shares. The EVP & Chief Medical Officer disposed these shares by way of transaction on Sep. 17, 2018. The company’s shares were given away at $3.5 per share worth to an income of some $535,500 to the account of Duliege Anne-Marie.

EVP & Chief Commercial Officer, Mayer Eldon C. III, purchased 100,000 common shares of Rigel Pharmaceuticals, Inc. (RIGL) in the open market. In a transaction dated Sep. 11, 2018, the shares were bought at an average price of $3.26, giving away a sum of $326,000. After this purchase, 215,000 common shares of RIGL are directly owned by the insider, with total stake valued at $531,050.

In the transaction dated Sep. 04, 2018, a great number of shares sold came courtesy the EVP & Chief Medical Officer; Duliege Anne-Marie disposed a total of 16,500 shares at an average price of $3.51, amounting to approximately $57,915. The insider now directly owns shares worth $.

Rigel Pharmaceuticals, Inc. (RIGL) Analyst Guide

Several analysts have released their opinion on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.71 average brokerage recommendation [T1].